Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jacob

Showing results (651-660 of 653) with videos related to

Pageof 66
Sort By:
You have reached the last page of results.This site can display upto 653 results.
The New England Journal of Medicine|September 8, 2021
Prospective, Multicenter, Controlled Trial of Mobile Stroke UnitsJames C Grotta, Jose-Miguel Yamal, Stephanie A Parker, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 13, 2020
Shared genetic background between children and adults with attention deficit/hyperactivity disorderPaula Rovira, Ditte Demontis, Cristina Sánchez-Mora, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 66

Showing results (651-660 of 653) with videos related to

Sort By:
Pageof 66
You have reached the last page of results.This site can display upto 653 results.
The New England Journal of Medicine|September 8, 2021
Prospective, Multicenter, Controlled Trial of Mobile Stroke UnitsJames C Grotta, Jose-Miguel Yamal, Stephanie A Parker, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 13, 2020
Shared genetic background between children and adults with attention deficit/hyperactivity disorderPaula Rovira, Ditte Demontis, Cristina Sánchez-Mora, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 66